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Purpose: To investigate the genetic associations of polypoidal choroidal vasculopathy (PCV), the genetic difference
between PCV and age-related macular degeneration (AMD), and the genotype-phenotype correlation of PCV.
Methods: A systematic review and meta-analysis were performed. Published articles about genetic associations of PCV
identified from a literature search were reviewed. The following data from individual studies were extracted and analyzed:
1) comparison of genetic polymorphisms between PCV and controls; 2) comparison of genetic polymorphisms between
PCV and AMD; and 3) comparison of phenotypes between different genotype groups.
Results: A total of 33 articles fulfilled the inclusion criteria. With meta-analyses, variants in four genes were found to be
significantly associated with PCV: LOC387715 rs10490924 (n=9, allelic odds ratio [OR]=2.27, p<0.00001), HTRA1
rs11200638 (n=4, OR=2.72, p<0.00001), CFH rs1061170 (n=4, OR=1.72, p<0.00001), CFH rs800292 (n=5, OR=2.10,
p<0.00001),  and  C2  rs547154  (n=3,  OR=0.56,  p=0.01).  LOC387715  rs10490924  was  the  only  variant  showing  a
significant difference between PCV and wet AMD (n=5, OR=0.66, p<0.00001). The risk genotypes of rs10490924 were
associated with larger lesion size, greater chance of vitreous hemorrhage, and worse therapeutic response in PCV.
Conclusions: LOC387715 rs10490924 was associated with PCV and its clinical manifestations, and showed a discrepant
distribution between PCV and AMD. Variants in HTRA1, CFH, and C2 were also associated with PCV.
Polypoidal  choroidal  vasculopathy  (PCV)  is  a  sight-
threatening disease in older adults. Clinically, it shares several
common  manifestations  with  wet  age-related  macular
degeneration  (AMD)  such  as  subretinal  exudation  and
hemorrhage  involving  the  macular  region.  PCV  was  first
identified as distinct from wet AMD in 1990 by Yannuzzi et
al.  [1],  who  reported  a  series  of  patients  with  peculiar
polypoidal, subretinal vascular lesions associated with serous
and  hemorrhagic  detachment  of  the  retinal  pigment
epithelium,  and  named  the  clinical  subtype  PCV.  Later,
researchers  reported  that  under  indocyanine  green
angiography  (ICGA),  PCV  demonstrated  the  distinct
characteristic of a branching network of vessels and dilation
at the ends of the vascular network in the inner choroid [2],
thus making ICGA a standard investigation for diagnosing
PCV.
The etiology of PCV remains largely unknown. It is likely
a multifactorial disease sharing some mechanisms with AMD.
To date, it is well recognized that genetic factors play an
important role in the pathogenesis of AMD. In 2005, a coding
single nucleotide polymorphism (SNP) rs1061170 (Y402H)
at the Complement factor H (CFH) gene was found to be
strongly associated with AMD in a genome-wide association
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study (GWAS) [3-7] in Caucasians. Subsequently, the SNP
rs10490924  at  LOC387715  (also  known  as  ARMS2)  and
rs11200638 at HTRA1 were found to be associated with AMD
in Caucasian and Asian populations [8-11]. Later, other genes
or loci were also discovered as risk or protective factors for
AMD, such as Complement factor B (CFB) [12], Complement
factor C2 [12], Complement factor C3 [13], SERPING1 [14],
and so on. The phenotypic similarities between AMD and
PCV lead to the hypothesis that genes involved in AMD may
also play a role in PCV. Therefore, investigating AMD genes
involved in PCV may easily reveal candidate genes for PCV
[15,16], providing insights into the pathogenesis of PCV; in
addition, differentiating the genetic profiles between PCV and
AMD may provide clues to whether PCV is a subtype of wet
AMD or a distinct disease [17], shedding some light on the
pathogenesis  of  the  respective  phenotypes.  Furthermore,
genotype-phenotype correlation analysis, especially genetic
predictors  of  therapy,  may  provide  guidelines  for  better
management of patients with AMD or PCV [18]. Thus far,
however, findings on the genetic profiles of PCV compared
to AMD remain controversial among different reports [17,
19,20].
Here, in an attempt to give the overall effects and solve
the controversies, we report a systematic review and meta-
analysis  summarizing  all  published  results  of  genetic
associations in PCV. This study 1) investigated which genetic
variants are significantly associated with PCV and their effect
sizes, 2) examined whether there are differences between the
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816genetic risks of PCV and AMD, and 3) summarized the results
of genotype-phenotype correlations in PCV.
METHODS
Literature search: A systematic literature search using the
databases PubMed, Embase, Web of Science, and the Chinese
Biomedical Database was conducted on October 30, 2011, to
identify all published studies on the association of genetic
polymorphisms with PCV and/or its phenotypes. The search
strategy (polypoidal choroidal vasculopathy OR PCV) AND
(gene OR genetic OR polymorphism OR variant OR DNA or
SNP) in All Fields was used. We did not use the option of
language  limitation  on  PubMed,  Embase,  or  Web  of
Science.
Review  process:  Two  reviewers  (H.Y.C.  and  K.L.)
independently reviewed the retrieved records. The following
inclusion criteria were applied during the review process: 1)
association study of genetic variants with PCV and/or its
phenotypes; 2) raw data of allele or genotype frequencies or
counts available; 3) the type of article an original research
study, not a review, case report, or editorial comment. For
studies published by the same group on the same gene and
markers, only the most recent article or the article with the
largest sample size was included for analysis. Independent
review and resolution by a third reviewer (L.J.C.) was sought
if the two reviewers disagreed.
Data extraction: The following data were extracted: author,
year of publication, ethnicity of study subjects, whether the
Hardy–Weinberg  equilibrium  (HWE)  was  examined  in
controls, the numbers and demographic characteristics of the
patients and controls, and the allele and genotype counts or
frequencies of each SNP in the patients and controls. The
allele counts were calculated from the genotype counts when
needed. We also calculated the allele or genotype counts from
the frequencies, rounding to the closest integer, for studies
[21,22] in which the genotype counts were not given. For the
analysis of the genotype-phenotype correlation, the following
phenotype  information  were  extracted  at  each  genotype
group: the gender and bilaterality counts, the case number, the
mean  and  standard  deviation  of  age  of  onset,  the  best-
corrected  visual  acuity  (BCVA),  greatest  linear  diameter
(GLD) of lesion on fluorescence fundus angiography (FFA)
and  ICGA,  and  BCVA  at  12  months  after  photodynamic
therapy or combined therapy. For the study [23] in which the
standard  deviation  was  not  given,  we  obtained  it  by
communicating  with  the  corresponding  author.  The  data
extraction and data input processes were performed by two
reviewers  (H.Y.C.  and  K.L.)  independently.  Further
independent review and resolution by a third reviewer (L.J.C.)
was sought if the two reviewers disagreed.
Data analysis: To investigate the associations of gene variants
with PCV, the allele and genotype frequencies of the SNPs
were  compared  between  PCV  and  normal  controls.  Six
genetic models were used in the association analysis: allele,
homozygote, heterozygote, dominant, recessive, and additive.
To investigate whether PCV and wet AMD have different
genetic  risks,  the  allele  frequencies  of  the  SNPs  were
compared between the patients with PCV and wet AMD in
the studies that included both disorders. To investigate the
genotype-phenotype  correlation,  the  phenotype  characters
were compared between patients carrying one or two risk
alleles and patients without the risk allele. The results of
individual studies were pooled using the software Review
Manager  (RevMan,  version  5.1.4,  The  Cochrane
Collaboration, Copenhagen, Denmark). In all of the meta-
analyses, the odds ratios (ORs) or mean differences (MDs)
and 95% confidence interval (CIs) were estimated with the
fixed or random model according to the heterogeneity test.
When the heterogeneity test α was <0.1, a random model was
applied; otherwise, a fixed model was applied. Egger’s test
was used to evaluate possible publication bias in the meta-
analysis with the number of included studies >2.
RESULTS
A total of 175 articles were identified from literature search,
including 43 from PubMed, 63 from Embase, 65 from Web
of Science, and four from the Chinese Biomedical Literature
Database.  Among  them,  79  were  excluded  because  of
duplication, 38 were excluded because of unrelated topics,
and 16 were excluded because of the publication type, such
as a review. The full text of the remaining 42 records was
retrieved and reviewed. Nine articles were excluded after the
full text was reviewed (Figure 1). Finally, 33 articles were
included for the meta-analysis. All the studies were case-
control  studies,  and  none  was  family  based.  The
characteristics of these articles are listed in Table 1.
All reported genetic associations in PCV are summarized
in Table 2. The SNP rs10490924 at LOC387715 was the most
investigated SNP in PCV. Four articles [24-27] were from the
same study group; only the most recent was used [27]. Nine
studies were included in the meta-analysis [16,22,27-33]. The
minor allele, T, was more frequent in PCV than in the controls
in all articles. The allelic OR in an individual study ranged
from 1.63 to 4.31, with a pooled OR of 2.27 (95% CI: 1.84–
2.79, p<0.00001, Figure 2A). No significant publication bias
was detected (Egger’s test p=0.202). The pooled ORs were
4.90,  1.74,  2.44,  3.26,  and  1.65  for  the  homozygote,
heterozygote,  dominant,  recessive,  and  additive  models,
respectively,  with  all  p<0.0001  (Appendix  1).  The  allele
frequencies of rs10490924 in PCV and AMD were reported
in five studies [22,27-29,34]. The T allele frequency was
lower in PCV compared to AMD in all reports, with a pooled
OR of 0.66 (95% CI: 0.57–0.76, p<0.00001, Figure 3A). No
significant  publication  bias  was  detected  (Egger’s  test
p=0.627).
The SNP rs11200638 located at the promoter of HTRA1
was investigated in five studies [16,25,32,33,35]. Two articles
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817[25,35] were from the same study group, and the earlier one
[35] was excluded. The A allele was more prevalent in PCV
than in the controls in all studies, with individual allelic ORs
ranging from 2.24 to 4.15. The pooled allelic OR was 2.72
(95% CI: 2.04–3.63, p<0.00001, Figure 2B). No significant
publication bias was detected (Egger’s test p=0.539). The
pooled  ORs  were  6.43,  1.75,  2.95,  4.50,  and  2.08  in  the
homozygote, heterozygote, dominant, recessive, and additive
models,  respectively  (all  p<0.001,  Appendix  2).  The
distributions of rs11200638 in PCV and AMD were reported
in two studies [16,25]. Although the frequencies of the A allele
in PCV were lower than in AMD in both studies, neither the
individual ORs nor the pooled OR (0.86, 95% CI: 0.64–1.16,
p=0.33, Figure 3B) was statistically significant.
The association of CFH rs1061170 (Y402H) with PCV
was  investigated  in  five  studies  [21,22,27,32,35],  among
which one [35] was excluded because the authors were from
the same group as those in a later article [27]. The C allele was
more frequent in PCV than in the controls. The OR in an
individual study was statistically significant in two studies
[22,27] but not in the other two [21,32]. The pooled allelic OR
was 1.72 (95% CI: 1.42–2.10, p<0.000001, Figure 2C). No
significant  publication  bias  was  detected  (Egger’s  test
p=0.912). The pooled ORs were statistically significant in the
heterozygote  (1.72),  dominant  (1.71),  and  additive  (1.57)
models, but not for the homozygote (1.48) or recessive (1.37)
model (Appendix 3). There was no significant difference in
the allele frequencies of rs1061170 between PCV and AMD,
with a pooled OR of 0.91 (95% CI: 0.71–1.18, p=0.49, Figure
3C). The association of CFH rs800292 (I62V) with PCV was
investigated in five studies [21,27,29,31,32]. The G allele was
more frequent in PCV than in the controls, with a pooled
allelic OR of 2.10 (95% CI: 1.87–2.37, p<0.00001, Figure
2D). No significant publication bias was detected (Egger’s
test, p=0.780). The pooled ORs were 4.06, 1.92, 2.81, 2.42,
and  1.67  in  the  homozygote,  heterozygote,  dominant,
recessive,  and  additive  models,  respectively,  with  all
p<0.00001  (Appendix  4).  The  allelic  distributions  of
rs800292 in PCV and AMD were reported in two studies
[27,29],  but  neither  the  individual  studies  nor  the  pooled
analysis (OR=0.95, 95% CI: 0.79–1.16, p=0.62, Figure 3D)
found a significant difference between PCV and AMD. The
CFH rs3753394 was reported in two studies [21,32] and the
pooled OR was 2.12 for the T allele (95% CI: 1.61–2.77,
p<0.00001, Figure 2E). The CFH rs1329428 was reported in
two studies [21,32] and the pooled OR was 1.74 for the C allele
(95%  CI:  1.33–2.28,  p<0.0001,  Figure  2F).  The  CFH 
rs1410996 was reported in two studies [21,22], and the pooled
OR was 1.82 for the C allele (95% CI: 1.39–2.37, p<0.0001,
Figure 2G).
At the CFB-C2 locus, the association of CFB rs415667
with PCV was investigated in three studies [21,22,32]. Neither
the individual OR nor the pooled OR (0.79, 95% CI: 0.40–
1.57,  p=0.50,  Figure  2H)  was  statistically  significant.  No
significant  publication  bias  was  detected  (Egger’s  test
p=0.907). Only one study compared the allele frequency of
Figure  1.  Flow  diagram  of  literature
screening. Flow diagram depicted the
screening process of retrieved articles,
including  the  number  and  reason  of
exclusion.
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820rs415667 between PCV and wet AMD, and the OR was 1.35
(p=0.50) [22]. The association of C2 rs547154 with PCV was
investigated in three studies [21,22,32]. The individual ORs
for the T allele ranged from 0.28 to 0.73, and only one was
statistically significant [22]. The pooled OR was 0.56 (95%
CI 0.36–0.87, p=0.01, Figure 2I). No significant publication
bias was detected (Egger’s test p=0.601). Only one study
compared the allele frequency of rs547154 between PCV and
wet AMD, and the OR was 0.74 (p=0.82) [22].
Regarding the other genes, the SNP rs2511989 at the
SERPING1 gene was reported in two studies [36,37], but none
of the original studies or the pooled analysis (OR=0.97, 95%
CI:  0.76–1.24,  p=0.80,  Figure  2J)  showed  a  statistically
significant association with PCV. A significant association
between rs2301995 in elastin and PCV was reported in one
Figure 2. The forest plots of meta-analysis compared the allelic frequencies between polypoidal choroidal vasculopathy and control. Squares
indicate the study-specific odds ratio (OR). The size of the box is proportional to the weight of the study. Horizontal lines indicate 95%
confidence interval (CI). A diamond indicates the summary OR with its corresponding 95% CI. A: LOC387715 rs10490924; B: HTRA1
rs11200638; C: Complement factor H (CFH) rs1061170; D: CFH rs800292; E: CFH rs3753394; F: CFH rs1329428; G: CFH rs1410996;
H: CFB rs415667; I: C2 rs547154; J: SERPING1 rs2511989; K: Elastin rs2301995; L: PEDF rs1136287.
Molecular Vision 2012; 18:816-829 <http://www.molvis.org/molvis/v18/a87> © 2012 Molecular Vision
821Figure 3. The forest plots of meta-analysis compared the allelic frequencies between polypoidal choroidal vasculopathy and age-related macular
degeneration. Squares indicate the study-specific odds ratio (OR). The size of the box is proportional to the weight of the study. Horizontal
lines  indicate  95%  confidence  interval  (CI).  A  diamond  indicates  the  summary  OR  with  its  corresponding  95%  CI.  A:  LOC387715
rs10490924; B: HTRA1 rs11200638; C: Complement factor H (CFH) rs1061170; D: CFH rs800292; E: Elastin rs2301995; F: PEDF
rs1136287.
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822study cohort [17], but not in the other three cohorts [19,20].
The pooled OR was 1.17 (95% CI: 0.97–1.41, p=0.11, Figure
2K). No significant publication bias was detected (Egger’s test
p=0. 0.721). A significant difference in the distributions of
rs2301995 between PCV and AMD was shown in one cohort
[17] but not in the other three [19,20], and the pooled OR was
1.07 (95% CI: 0.68–1.70, p=0.77, Figure 3E, Egger’s test
p=0.233). Association of PEDF rs1136287 with PCV was
reported in two studies [38,39], but no individual studies or
the pooled analysis showed a significant association (Figure
2L). The allelic distributions of rs1136287 in PCV and AMD
were not significantly different (Figure 3F). The associations
of SNPs at SOD2 [40], PEDF [38], TLR3 [41], 9p21 [42],
RDBP  [21],  SKIV2L  [21],  and  C3  [29]  with  PCV  were
reported  in  one  article  (Table  2).  No  meta-analysis  was
performed on these genes/loci.
Genotype-phenotype  correlations  of  LOC387715
rs10490924 were investigated in nine articles [18,23,30,31,
33,34,43-45].  Four  articles  [18,23,30,44]  were  written  by
Sakurada’s group and another two [33,43] by Park’s group.
Only the latest or largest data were included in the meta-
analysis.  Correlation  of  gender  with  rs10490924  was
investigated in three studies [23,34,43]. Neither the original
studies nor the meta-analysis showed a statistically significant
difference  in  gender  between  different  genotype  groups
(Figure 4A,B). One study [23] reported the mean age of onset
in  the  TT  genotype  group  was  younger  than  in  the  GG
genotype group. However, two other studies [34,43] and the
pooled analysis showed a lack of significant difference in age
of onset between different genotype groups (Figure 4C,D). A
study  reported  that  patients  with  the  TT  genotype  of
rs10490924 were more likely to have bilateral involvement
compared to patients with the GG genotype [23]. However, a
lack of significant correlation was reported in another study
[33], and revealed by our meta-analysis (Figure 4E). Two
studies reported that patients with the risk genotypes TT and
TG  had  worse  BCVA  compared  to  those  with  the  GG
genotype [23,33]. However, in another study the result was
reversed,  although  the  difference  was  not  statistically
significant  [34].  The  meta-analysis  did  not  support  a
significant difference in BCVA between the genotype groups
(Figure 4G,H). Studies have reported that the FFA GLD in
patients with the TT genotype was larger compared to those
with the GG genotype in three studies [18,33,34]. Pooled
analyses showed the mean difference was 1.21 mm (TT versus
GG, 95% CI: 0.64–1.77, p<0.0001, Figure 4I), while the mean
difference in FFA GLD between the TG and GG genotype
groups was not statistically significant (Figure 4J). There was
also a statistically significant difference in the ICGA GLD
between  the  TT  and  GG  genotype  groups  (pooled
MD=0.57 mm, 95% CI: 0.17–0.96 mm, p=0.005, Figure 4K),
as well as between the TG and GG genotype groups (pooled
MD=0.46 mm, 95% CI: 0.05–0.87, p=0.03, Figure 4L). A
study also reported that the T allele or TT genotype was
associated with larger PCV (lesion size greater than 1 disc
diameter) [45]. However, no mean or standard deviation for
each genotype was reported in the article; therefore, it was not
included in the meta-analysis. Association of rs10490924 with
the risk of vitreous hemorrhage was reported in two studies
[30,33].  The  pooled  OR  was  6.52  (95%  CI:  0.83–51.03,
p=0.07, Figure 4M) and 1.00 (95% CI: 0.10–10.04, p=1.00,
Figure 4N) for homozygote and heterozygote, respectively.
Since the heterozygote OR was 1, we analyzed it using the
recessive and allelic models, and the pooled ORs were 12.15
(95% CI: 2.72–54.21, p=0.001, Figure 4O) and 10.41 (95%
CI: 2.47–43.88, p=0.001 Figure 4P), respectively. The BCVA
12 months after PDT or combined therapy was better in the
GG genotype group than in the TT genotype group; the mean
difference was 0.39 LogMAR (95% CI 0.10–0.68, p=0.008,
Figure 4Q). The mean difference between the TG and GG
genotype  groups  was  0.20  LogMAR  lines  but  was  not
statistically significant (p=0.20, Figure 4R). The associations
of  bilaterality  and  lesion  size  of  PCV  with  HTRA1 
rs11200638 were also investigated [33,35]. However, neither
the  original  studies  nor  the  pooled  analysis  showed  a
significant correlation (Figure 5).
DISCUSSION
In this systematic review and meta-analysis, we identified 33
genetic  studies  of  PCV.  After  the  individual  results  were
pooled, the LOC387715 rs10490924, HTRA1 rs11200638,
CFH  rs1061170,  rs800292,  rs3753394,  rs1329428  and
rs1410996, and C2 rs547154 were found to be significantly
associated with PCV. In addition, by comparing the variants
between  PCV  and  AMD,  only  the  rs10490924  showed  a
statistical  difference.  Furthermore,  by  analyzing  the
genotype-phenotype  correlation,  we  found  that  the  risk
genotypes of rs10490924 were associated with larger lesion
size,  greater  chance  of  vitreous  hemorrhage,  and  worse
response to therapy in PCV.
To date, a group of genetic risk factors for AMD has been
identified. This helps us understand not only the etiology and
pathogenesis but also the diagnosis and management of this
ophthalmic condition. In view of the phenotypic similarities
between  AMD  and  PCV,  the  genes  for  AMD  are  good
candidates for genetic studies of PCV. Until now, almost all
reported AMD-associated genes have been investigated in
PCV, including LOC387715, HTRA1, CFH, C2, CFB, C3,
SERPING1, PEDF, Elastin, TLR3, RDBP, and SKIV2L.
With  this  systematic  review  and  meta-analysis,  the
association of LOC387715 rs10490924 was confirmed, with
the overall allelic OR 2.27. The homozygote and heterozygote
ORs were 4.90 and 1.74, respectively, suggesting an additive
genetic effect. A study reported that LOC387715 encoded a
mitochondrial membrane protein and was expressed in the
retina [46]. The association of LOC387715 with PCV suggests
that mitochondrial disorders may play an important role in
Molecular Vision 2012; 18:816-829 <http://www.molvis.org/molvis/v18/a87> © 2012 Molecular Vision
823Figure 4. The forest plots of meta-analysis compared the phenotypes of polypoidal choroidal vasculopathy between different genotypes of
LOC387715 rs10490924. Blue squares indicate the study-specific odds ratio (OR). Green squares indicate the study-specific mean difference
(MD). The size of the box is proportional to the weight of the study. Horizontal lines indicate 95% confidence interval (CI). A diamond
indicates the summary OR (blue) or MD (green) with its corresponding 95% CI. A, C, E, G, I, K, M and Q: comparison between TT and
GG; B, D, F, H, J, L, N and R: comparison between TG and GG. O: comparison between TT and TG + GG; P: comparison between T and
G allele. A and B: Gender distribution; C and D: Age of onset; E and F: Bilaterality; G and H: Best-corrected visual acuity; I and J: Greatest
linear diameter on fundus fluorescence angiography; K and L: Greatest linear diameter on indocyanine green angiography; M-P: Vitreous
hemorrhage; Q and R: Best-corrected visual acuity at 12 months after photodynamic therapy or combined therapy.
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824PCV  pathogenesis.  Another  variant  at  the  10q26  region,
HTRA1 rs11200638, was also confirmed to be associated with
PCV.  A  study  reported  that  HTRA1  transgenic  mice  had
retinal  pigment  epithelium  induced  choroidal  branching
vascular networks, polypoidal lesions, severe degeneration of
the elastic laminae, and tunica media of choroidal vessels
[47],  suggesting  that  overexpression  of  HTRA1  may
predispose  individuals  to  PCV.  To  date,  whether  the
LOC387715 or the HTRA1 at 10q26 is the gene responsible
for AMD and PCV remains in question because of the strong
linkage disequilibrium between them. However, this issue
cannot be solved in our current meta-analysis, and awaits
further  functional  characterizations.  The  associations  of
CFH  rs1061170,  rs800292,  rs3753394,  rs1329428,  and
rs1410996, and C2 rs547154 were also confirmed, suggesting
that the complement system and inflammatory pathways may
also play an important role in the pathogenesis of PCV. The
variants  RDBP  rs3880457,  SKIV2L  rs2075702,  and  C3
rs2241394 were also reported in one article to be associated
with PCV, suggesting a role for the immunological system in
PCV.  In  contrast,  polymorphisms  at  SERPING1,  elastin,
SOD2, PEDF, and TLR3 were not associated with PCV.
There  are  some  common  and  distinct  clinical
characteristics between PCV and AMD. Both PCV and wet
AMD usually involve older adults. However, patients with
PCV tend to be younger. The prevalence of AMD is higher in
Caucasians than in Asian and black populations, while the
prevalence of PCV is higher in Asians and Africans than in
Caucasians.  Eyes  with  PCV  usually  lack  drusen—a
characteristic sign of early AMD. However, some cases have
demonstrated clinical manifestations of PCV and dry or wet
AMD. Although PDT and anti-vascular endothelial growth
factor (VEGF) therapies are therapeutic opinions for PCV and
AMD, the responses to treatments between these two diseases
are different. PCV seemingly has a better response to PDT but
poorer response to anti-VEGF agents such as bevacizumab
[48]. In view of such controversies, whether PCV is a subtype
of AMD or a specific entity of disorder remains unsolved, and
one solution is to compare the genetic etiology of PCV and
AMD.
Through a systematic review, we identified 22 articles
reporting the genetic associations of 11 genes with PCV and
AMD,  including  LOC387715,  HTRA1,  CFH,  CFB,  C2,
SERPING1, elastin, SOD2, PEDF, TLR3, and 9p21. Among
them, only LOC387715 rs10490924 was statistically different
between PCV and AMD, with an allelic OR of 0.66 (95% CI:
0.57–0.76, p<0.00001). This difference suggests that although
LOC387715 is associated with PCV and AMD, its effect could
be less strong in PCV than in AMD. In view of the distinct
difference in the prevalence of PCV between Caucasian and
Asian populations with a comparable frequency of the risk
allele,  there  could  be  yet-to-be-identified  genetic  or
environmental  factors  guiding  the  development  of  each
phenotype. However, the variants in other genes were not
statistically  different  between  PCV  and  AMD,  including
HTRA1 rs11200638, CFH rs1061170, CFH rs800292, and
C2 rs547154. The failure in differentiation may be due to the
small overall ample size from a limited number of studies,
especially for the eight variants studied in only one article, and
needs further investigation.
Genotype-phenotype correlation may shed light on the
pathogenesis  and  clinical  management  of  disease.  In  this
meta-analysis, we found that LOC387715 rs10490924 was
statistically  associated  with  lesion  size  and  vitreous
hemorrhage in PCV, with the risk genotype TT associated
with a larger lesion and a greater risk of vitreous hemorrhage,
that is, more severe phenotypes. This may support the role of
LOC387715 in the pathogenesis of PCV. The association of
rs10490924 with gender, age of onset, bilaterality, and BCVA
is controversial. The association of HTRA1 rs11200638 and
bilaterality or BCVA is also controversial. The rs10490924
genotype was also correlated with the therapeutic response in
Figure 5. The forest plots of meta-analysis compared the phenotypes of polypoidal choroidal vasculopathy between different genotypes of
HTRA1 rs11200638. Blue squares indicate the study-specific odds ratio (OR). Green squares indicate the study-specific mean difference (MD).
The size of the box is proportional to the weight of the study. Horizontal lines indicate 95% confidence interval (CI). A diamond indicates the
summary OR (blue) or MD (green) with its corresponding 95% CI. A and C: Comparison between TT and GG; B and D: Comparison between
TG and GG. A and B: Bilaterality; C and D: Greatest linear diameter on fundus fluorescence angiography.
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825PCV. The risk genotypes, TT or TG, are associated with
poorer therapeutic response, and the mean difference was 0.39
and 0.20 LogMAR lines, respectively. These results provide
pharmacogenetics  evidence  for  estimating  the  visual
prognosis after therapies for PCV.
One  advantage  of  this  systematic  review  and  meta-
analysis is an overview of all published genetic studies in
PCV, demonstrating the overall effects and, at least partially,
resolving the controversies. There are also some limitations
in this study. First, the number of original studies was limited
for some genes, and the conclusions may not be sufficiently
strong. Second, the quality of the meta-analysis depends on
the quality of the original studies. In some studies, the HWE
was not examined in the control group; thus, quality control
was lacking. Third, there was significant heterogeneity among
studies of some polymorphisms. The source of heterogeneity
may include the small sample size in some studies and the
different  clinical  characteristics  of  patients  in  different
studies. A random effect model was used for the meta-analysis
when statistically significant heterogeneity was met. Since
most reports were by Eastern Asians, especially Japanese, and
there was only one report by one group about a Caucasian
population,  no  subgroup  analysis  was  performed.  Fourth,
there may be an imbalance between the case and control
groups. For example, the gender or age may be different
between  groups  in  some  articles.  The  imbalance  can  be
corrected with multivariate analysis in the original studies, but
cannot be handled in the meta-analysis. This may also be a
cause of heterogeneity. Fifth, we did not search Japanese
databases.  Although  some  Japanese  medical  journals  are
indexed in PubMed and Embase, we still may have missed
some articles in Japanese or other languages. Finally, only one
GWAS of PCV [29] has been published, and we could not
perform  a  meta-analysis  of  GWASs  to  identify  new  loci/
polymorphisms associated with PCV.
In  conclusion,  in  this  systematic  review  and  meta-
analysis of 33 articles reporting genetic associations in PCV,
polymorphisms at LOC387715, HTRA1, CFH, and C2 were
found to be significantly associated with PCV. LOC387715
rs10490924  was  the  only  variant  showing  a  significant
difference between PCV and AMD. This variant was also
correlated  with  lesion  size,  vitreous  hemorrhage,  and
therapeutic  response  in  PCV.  Further  investigations  are
necessary to confirm the roles of those genes reported in a
limited number of original studies.
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828Appendix 1. Meta-analysis of the association of LOC387715 rs10490924
with polypoidal choroidal vasculopathy in different genetic models.
Squares indicate study-specific OR; the size of the box is
proportional  to  the  weight  of  the  study;  horizontal  lines
indicate  95%  confidence  interval  (CI);  diamond  indicates
summary OR with its corresponding 95% CI. A: homozygote;
B: heterozygote; C: dominant model; D: recessive model; E:
additive model. To access the data, click or select the words
“Appendix 1.” This will initiate the download of a compressed
(pdf) archive that contains the file.
Appendix 2. Meta-analysis of the association of HTRA1 rs11200638 with
polypoidal choroidal vasculopathy in different genetic models.
Squares indicate study-specific OR; the size of the box is
proportional  to  the  weight  of  the  study;  horizontal  lines
indicate  95%  confidence  interval  (CI);  diamond  indicates
summary OR with its corresponding 95% CI. A: homozygote;
B: heterozygote; C: dominant model; D: recessive model; E:
additive model. To access the data, click or select the words
“Appendix 2.” This will initiate the download of a compressed
(pdf) archive that contains the file.
Appendix  3.  Meta-analysis  of  the  association  of  Complement  factor  H
rs1061170  with  polypoidal  choroidal  vasculopathy  in  different  genetic
models.
Squares indicate study-specific OR; the size of the box is
proportional  to  the  weight  of  the  study;  horizontal  lines
indicate  95%  confidence  interval  (CI);  diamond  indicates
summary OR with its corresponding 95% CI. A: homozygote;
B: heterozygote; C: dominant model; D: recessive model; E:
additive model. To access the data, click or select the words
“Appendix 3.” This will initiate the download of a compressed
(pdf) archive that contains the file.
Appendix  4.  Meta-analysis  of  the  association  of  Complement  factor  H
rs800292  with  polypoidal  choroidal  vasculopathy  in  different  genetic
models.
Squares indicate study-specific OR; the size of the box is
proportional  to  the  weight  of  the  study;  horizontal  lines
indicate  95%  confidence  interval  (CI);  diamond  indicates
summary OR with its corresponding 95% CI. A: homozygote;
B: heterozygote; C: dominant model; D: recessive model; E:
additive model. To access the data, click or select the words
“Appendix 4.” This will initiate the download of a compressed
(pdf) archive that contains the file.
Molecular Vision 2012; 18:816-829 <http://www.molvis.org/molvis/v18/a87> © 2012 Molecular Vision
Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China.
The print version of this article was created on 1 April 2012. This reflects all typographical corrections and errata to the article
through that date. Details of any changes may be found in the online version of the article.
829